At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
High concentration of Allo-ASC +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Intractable Common Extensor Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Allo-ASC): a Phase II Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating High concentration of Allo-ASC, Low concentration of Allo-ASC, and 2 other interventions for Lateral Epicondylitis. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The aim of this study is to evaluate the efficacy and safety of intra-tendon injection of allogeneic adipose-derived mesenchymal stem cells (Allo-ASC) in intractable common extensor tendinosis patients in comparison with a control treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Epicondylitis
CountriesSouth Korea
CollaboratorsKorea Health Industry Development Institute
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMar 2018
Primary CompletionJul 2019
Study CompletionMar 2021
TodayJul 2026
First PostedFeb 28, 2018
Enrollment StartMar 15, 2018
Primary CompletionJul 16, 2019
Study CompletionMar 8, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.3 years ago
Interventions
High concentration of Allo-ASCbiological
10 million cells of Allo-ASC 0.5cc
Low concentration of Allo-ASCbiological
1 million cells of Allo-ASC 0.5cc
Fibrin gluedrug
Fibrin glue 0.5cc
Normal salinedrug
Normal saline 0.5cc